How Are Technological Developments Improving Oligonucleotides?

 A surge in research activities in synthetic biology and improvement in oligonucleotide synthesis have led to the development of advanced oligonucleotides. Recent innovations in synthesis techniques have led to the swift and cost-effective synthesis of oligomers. Moreover, the developments of novel sets of protecting amino groups, better coupling reagents, and high-throughput synthesizers have transformed the synthesis of oligonucleotides. These advancements will propel the oligonucleotide synthesis market at 10.8% CAGR during 2018–2023. At this rate, the market is expected to reach $2.8 billion by 2023 from $1.5 billion in 2017.

Read the full report - Oligonucleotide Synthesis Market Size and Demand Forecast 

In the same vein, the evolution of microarray technology has assisted the development of oligonucleotide products for therapeutic and diagnostic processes. For example, research of numerous oligonucleotides with biological ligands has led to its increased application in the diagnosis of several inherited disorders. Similarly, constant improvement in microchip-based oligonucleotide synthesis has led to the surge in throughput and decrease in cost of synthesis of oligonucleotides. Additionally, developments in technologies, such as enzymatic error correction, have led to the reduction in frequency of errors in synthesized products.

Apart from this, academic research institutes, food and beverage companies, diagnostic laboratories, forensic laboratories, and pharmaceutical and biotechnology companies use oligonucleotides for various applications. Among these end users, the diagnostic laboratories use the highest volume of oligonucleotides for diagnostic purposes, on account of their increasing applications in molecular diagnosis of inherited disorders. Besides, the academic research institutes also use these products in large quantities as probes in antisense analyses, microarray, and in-situ hybridization.

Due to widening application base, market players are focusing on improving and expanding their product portfolios. For instances, Thermo Fisher Scientific Inc., in October 2017, launched Applied Biosystems Axiom Africa Array for commercial purposes. The product was introduced for medical and population genomics to support and accelerate global health research. Thermo Fisher Scientific Inc. and The Wellcome Trust Sanger Institute combined their respective expertise in informatics and human genomic analysis to co-develop Applied Biosystems Axiom Africa Array that assists in capturing genome variation in the European, African, and Asian populace.

Thus, the continuous advancements in technologies coupled with high prevalence of life-threatening diseases that demand early diagnosis and treatment will fuel the adoption of oligonucleotides in the coming years. 

Read More

Oligonucleotide Synthesis Market is Ultimately Generating $2.8 Billion in Revenue by 2023

Valued at $1.5 billion in 2017, the oligonucleotide synthesis market size is predicted to progress with a 10.8% CAGR during the forecast period 2018–2023, ultimately generating $2.8 billion in revenue by 2023. By definition, oligonucleotide synthesis is the artificial creation of oligonucleotides, which are short DNA or RNA fragments.

On the basis of offering, reagents and consumables, synthesized oligonucleotides, and equipment are the three market categories. Among these, synthesized oligonucleotides held the largest revenue share (76.3%) in 2017 and is also predicted to grow the fastest during the forecast period, at an 11.1% CAGR. The increase in contract manufacturing of DNAs and RNAs is expected to escalate the demand for synthesized oligonucleotides. Similarly, when segmented by application, the oligonucleotide synthesis market can be categorized into diagnostics, research, and therapeutics.

To Learn more About this report@ http://bit.ly/2UrgrJx

Among all, the research category led the market in 2017 and is expected to be the fastest growing (11.1% CAGR) category. This pays credence to the finding that of all the end users of synthetic oligonucleotides, including diagnostic laboratories, pharmaceutical and biotechnology companies, academic research institutes, and others, academic research institutes dominated the oligonucleotide synthesis market in 2017 with 40.4% revenue share. This further substantiates the fact that increasing research activities in the field is one of the key growth drivers of the market.

In addition, several new products have come in the oligonucleotide synthesis market, such as protecting amino groups, synthesizers with high throughput, and coupling reagents. Similarly, the development of the microarray technology is aiding the production of oligonucleotides for the diagnosis and treatment of diseases. Along with making the nucleotide assembly method efficient and correcting errors in synthesized enzymes, such developments are also helping in the steady progress of the market.

Now, the oligonucleotide R&D is itself being bolstered by growing government support in the form of funding and other initiatives. The U.S. government invested about $820 million in synthetic biology R&D between 2008 and 2014. Similarly, as per SynbiCITE an England-based organization, the U.K government invested over $400 million during 2009–2016 for establishing three training centers and six research institutes dedicated to synthetic biology. Thus, with favorable government attitude toward providing people with better levels of healthcare, the oligonucleotide synthesis market is predicted to continue on the path to prosperity.

Hence, it is clear that the increase in research and development in the synthetic biology field will further the market advance.

Read More